The Anondita Medicare IPO is scheduled to open on August 22, 2025, and close on August 26, 2025, with a price band of ₹137 to ₹145 per share. Based in New Delhi, Anondita Medicare specializes in manufacturing flavored male condoms, marketed primarily under the brand ‘COBRA’. With an installed capacity of nearly 562 million condoms per annum, the company caters to both domestic and international markets. The growing awareness of sexual health and the increasing demand for quality contraceptive products support the company’s growth. The Anondita Medicare IPO offers investors an opportunity to participate in the expanding healthcare and personal care sector in India.
₹80
₹145
₹275.50
Expert Opinions
The Anondita Medicare IPO is receiving positive market sentiment due to its strong presence in the niche segment of flavored male condoms and consistent financial performance. The company’s strengths include a well-established brand, robust manufacturing capacity, and a growing presence in export markets, mainly in Asia and Africa. For FY 2025, Anondita Medicare reported an impressive Return on Equity (ROE) of 41.71%, Return on Capital Employed (ROCE) of 37.42%, and a Net Asset Value (NAV) of ₹21.32, reflecting high profitability and efficient capital use.
Risks include dependency on raw material prices, regulatory challenges, and competitive pressures from both domestic and international players. From a long-term investment perspective, the Anondita Medicare IPO offers a compelling opportunity to gain exposure to the growing healthcare and personal care products market driven by increasing awareness and demand for quality contraceptives.
Investor Considerations
The Anondita Medicare IPO showcases strong company performance and solid fundamentals, with a Price to Book Value of 15.07, a robust PAT margin of 21.32%, and a manageable debt-to-equity ratio of 0.70 for FY 2025. Operating in the healthcare and personal care sector, the company benefits from increasing consumer awareness about sexual health and rising demand for quality contraceptive products. The sector outlook remains positive due to growing adoption in domestic and international markets and expanding distribution channels.
Growth prospects are supported by capacity expansion plans and market penetration strategies. Risks involve regulatory compliance, raw material price volatility, and competitive pressures. The Anondita Medicare IPO is suitable for long-term investors aiming to capitalize on sector growth, while short-term investors should account for price volatility and market fluctuations specific to the healthcare industry.
| Date | GMP | Trend |
|---|---|---|
| 26 Aug 2025 15.23 | ₹80 | Up |
| 25 Aug 2025 18.45 | ₹70 | Up |
| 24 Aug 2025 11.54 | ₹65 | --- |
| 23 Aug 2025 18.26 | ₹65 | --- |
| 22 Aug 2025 10.55 | ₹65 | Up |
| 21 Aug 2025 18.46 | ₹60 | Up |
| 20 Aug 2025 11.15 | ₹00 | --- |
| 19 Aug 2025 17.36 | ₹00 | --- |
FAQs
The Grey Market Premium showed moderate accuracy in predicting Anondita Medicare IPO’s listing performance. With a final GMP of ₹80, it projected a premium of 55.17% over the issue price of ₹145. The stock listed at ₹275.50, delivering a gain of 89.66%. This resulted in a prediction error of 34.49%, where the GMP correctly signaled a strong positive listing but underestimated the actual gain, reflecting fair reliability in this case.
Anondita Medicare IPO Current GMP is ₹70.
Anondita Medicare IPO Expected Returns is 48.28%.
Anondita Medicare IPO estimated listing price is ₹215.